Point72 Asia (Singapore) Pte. Ltd. Bio Atla, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $532 Billion
- Q3 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Bio Atla, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 36,899 shares of BCAB stock, worth $23,984. This represents 0.01% of its overall portfolio holdings.
Number of Shares
36,899
Previous 72,193
48.89%
Holding current value
$23,984
Previous $98.9 Million
34.34%
% of portfolio
0.01%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding BCAB
# of Institutions
65Shares Held
17.4MCall Options Held
500Put Options Held
33.5K-
Israel Englander Millennium Management LLC | New York, Ny2.66MShares$1.73 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.52MShares$1.64 Million0.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.89MShares$1.23 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.86MShares$1.21 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA874KShares$568,1490.13% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $23.6M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...